HYDERABAD: Hyderabad-based vaccine maker Biological E Limited will soon get mRNA technology from WHO’s technology transfer hub to develop a Covid vaccine. It developed a recombinant sub-unit protein vaccine, Corbevax, for Covid.
BE was selected by WHO’s advisory committee on vaccine product development (ACPDV) as a recipient of mRNA technology after examining several proposals from India, WHO said in a statement. With this, WHO and its partners will work with the Indian government and BE to develop a roadmap and put in place the necessary training and support for the Hyderabad-based player to start producing mRNA. “Primarily set up to address the Covid-19 emergency, the hub has the potential to expand manufacturing capacity for other products as well, including treatments, and target other priorities such as malaria, HIV and cancer,” WHO said.
BE, in fact, is working on an mRNA Covid vaccine that is in the early stages of development and is expected to start clinical trials in the second half of 2022, BE managing director Mahima Datla had told TOI in an exclusive interview early February. Terming the development a milestone in the company’s efforts to produce affordable vaccines for the world, Datla said BE has been investing in mRNA technologies since last year. “This partnership with WHO will enhance our ability to develop next generation mRNA vaccines that could be more suitable globally and expand the reach of vaccines availability worldwide,” Datla said on Monday.
BE was selected by WHO’s advisory committee on vaccine product development (ACPDV) as a recipient of mRNA technology after examining several proposals from India, WHO said in a statement. With this, WHO and its partners will work with the Indian government and BE to develop a roadmap and put in place the necessary training and support for the Hyderabad-based player to start producing mRNA. “Primarily set up to address the Covid-19 emergency, the hub has the potential to expand manufacturing capacity for other products as well, including treatments, and target other priorities such as malaria, HIV and cancer,” WHO said.
BE, in fact, is working on an mRNA Covid vaccine that is in the early stages of development and is expected to start clinical trials in the second half of 2022, BE managing director Mahima Datla had told TOI in an exclusive interview early February. Terming the development a milestone in the company’s efforts to produce affordable vaccines for the world, Datla said BE has been investing in mRNA technologies since last year. “This partnership with WHO will enhance our ability to develop next generation mRNA vaccines that could be more suitable globally and expand the reach of vaccines availability worldwide,” Datla said on Monday.
For all the latest business News Click Here
Denial of responsibility! TechAI is an automatic aggregator around the global media. All the content are available free on Internet. We have just arranged it in one platform for educational purpose only. In each content, the hyperlink to the primary source is specified. All trademarks belong to their rightful owners, all materials to their authors. If you are the owner of the content and do not want us to publish your materials on our website, please contact us by email – [email protected]. The content will be deleted within 24 hours.
